A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
Authors Park SH, Han X, Lobo F, Nanji S, Patel D
Received 28 May 2020
Accepted for publication 9 September 2020
Published 15 October 2020 Volume 2020:12 Pages 589—594
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Dean Smith
Sang Hee Park,1 Xue Han,2 Francis Lobo,2 Sakina Nanji,1 Dipen Patel1
1Modeling and Meta-Analysis, Pharmerit International, Bethesda, MD, USA; 2WW HEOR Markets-US, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA
Correspondence: Xue Han
Bristol-Myers Squibb Company, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA
Tel +1 213-309-9719
Fax +1 609 302 5808
Purpose: The primary objective of this study was to compare the cost per responder (CPR) between abatacept and adalimumab among seropositive rheumatoid arthritis (RA) patients.
Patients and Methods: CPR analysis was conducted from a US payer perspective over 24 weeks for early moderate-to-severe seropositive RA patients. Efficacy data (American College of Rheumatology [ACR] improvement criteria [ACR20/50/70] and DAS28-C reactive protein < 2.6) for abatacept and adalimumab were sourced from the post hoc analysis of the Early AMPLE trial (NCT02557100). Medication costs were considered assuming complete adherence. A 30% rebate was applied for adalimumab in the base case.
Results: At week 24, the total per patient pharmacy cost was $26,273.34 and $21,731.18, whereas the CPR (using ACR70 as the responder definition) was $46,337.46 and $74,935.10 (difference of -$28,597.64) for abatacept and adalimumab, respectively. The CPR was consistently lower for abatacept compared to adalimumab across all clinical measures, with differences ranging from -$7099.32 to -$43,608.97.
Conclusion: While the pharmacy cost was higher for abatacept compared to adalimumab, due to its higher clinical efficacy, the CPR was consistently lower for seropositive RA patients treated with abatacept. The results may be useful for healthcare decision-makers in understanding how to optimize treatment for seropositive RA patients while minimizing costs in today’s budget-constrained health environment.
Keywords: positive shared epitope, anti-citrullinated protein antibodies, anti-cyclic citrullinated peptide, rheumatoid factor, biomarker, seropositive
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]